Answers are grounded in this paper and cite their sources.
Aims The rapid emergence of multidrug-resistant Pseudomonas aeruginosa necessitates novel therapeutic strategies. This study aims to identify clinically approved drugs that can be repurposed as quorum sensing (QS) inhibitors to attenuate bacterial virulence and enhance antibiotic efficacy. Methods and Results Through virtual molecular docking against LasR, RhlR, and PqsR receptors, we identified chlorothiazide (CTZ) as a multi-target QS inhibitor. Phenotypic assays showed that CTZ significantly inhibited biofilm formation, pyocyanin production, extracellular protease activity, and motility in P. aeruginosa without affecting bacterial growth. Mechanistic studies using exogenous signal restoration, qPCR, and signal-deficient mutants confirmed that CTZ directly interferes with the Las, Rhl, and Pqs QS systems. CTZ also exhibited synergistic antibacterial activity with polymyxin B in vitro, reducing its MIC against multiple clinical isolates. In vivo, CTZ protected Caenorhabditis elegans from P. aeruginosa infection and, when combined with subtherapeutic polymyxin B, significantly improved survival and reduced bacterial load in a mouse acute pulmonary infection model. Conclusions CTZ functions as a promising anti-virulence adjuvant that potentiates conventional antibiotics, offering a dual strategy to improve treatment efficacy while mitigating resistance development.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: